Myriad Genetics Inc.
) gained 1.78% at yesterday's close, soon after the company
announced favorable data from the Milieu Interieur Project that
was published in the journal
. This initial data was published jointly by Myriad Genetics'
wholly owned subsidiary, Myriad RBM and privately held Institut
Pasteur, a non-profit foundation working on prevention and cure
of infection diseases.
The Milieu Interieur Project is a population-based study
undertaken with the aim to characterize the immune phenotypes of
1,000 healthy subjects in response to 32 complex immune
stimulants. This study has been supported by the French National
Ministry of Research and coordinated by the Institut Pasteur.
The results in the
journal show that Myriad RBM's TruCulture (a proprietary blood
collection and culturing system used to characterize individual
immune responses of 25 healthy people to medically relevant
stimuli) stimulations are reproducible, with close correspondence
in repeated tests from the same subject. According to Myriad
Genetics, the outcome of this project may create a landmark
making way for the development of cutting-edge diagnostics and
Myriad Genetics is currently targeting expansion of its
pipeline with products for diverse indications including
oncology, women's health, urology, dermatology, autoimmune and
inflammatory disease and neuroscience. To achieve this objective,
the company has decided to pursue internal developments,
in-licensing of technologies and acquisitions to expand its
business. We are sanguine about these developments as some of the
pipeline candidates look promising enough to cater to a
billion-dollar market size.
Myriad Genetics' increasing focus on the companion diagnostic
market should work in its favor fuelling growth. We look forward
to the expansion of indications and derive comfort from the
company's plan to foray into the dermatology, autoimmune and
neuroscience market in the near future, on the back of portfolio
Currently, the stock carries a Zacks Rank #2 (Buy). Some other
well-placed stocks that are worth a look are
Alexion Pharmaceuticals, Inc.
Gilead Sciences Inc.
). While ALXN and GILD hold a Zacks Rank #1 (Strong Buy), ALIOF
carries a Zacks Rank #2.
ACTELION LTD (ALIOF): Get Free Report
ALEXION PHARMA (ALXN): Free Stock Analysis
GILEAD SCIENCES (GILD): Free Stock Analysis
MYRIAD GENETICS (MYGN): Free Stock Analysis
To read this article on Zacks.com click here.